Programme

Host: ALS Liga België vzw

Organised by the Motor Neurone Disease Association in co-operation with the International Alliance of ALS/MND Associations
Organiser of the symposium:

Motor Neurone Disease Association
PO Box 246, Northampton NN1 2PR, UK
Tel: (-) 44 1604 611845 or 611822
Fax: (-) 44 1604 611858
Email: symposium@mndassociation.org
Website: www.mndassociation.org

Host for the symposium:

ALS Lliga België vzw
Campus Sint Rafaël, Block H, 4th floor
Kapucijnenvoer 33 B/1,
3000 Leuven, Belgium
Tel: (-) 32 (0) 16 23 95 82
Fax: (-) 32 (0) 16 29 98 65
Email: info@alsliga.be
Website: www.alsliga.be

Held in co-operation with:

The International Alliance of ALS/MND Associations
Tel: (-) 1 215 568 2462
Fax: (-) 1 215 543 3366
Email: alliance@als-mnd.org
Website: www.alsmndalliance.org

CME Accreditation

The 25th International Symposium on ALS/MND has been approved by the Federation of the Royal College of Physicians of the United Kingdom for 15 category 1 (external) CPD credit(s).

The ‘25th International Symposium on ALS/MND’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The ‘25th International Symposium on ALS/MND’ is designated for a maximum of 14 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
Welcome

Welcome to Brussels!

ALS Liga Belgium is proud to host the 25th International Symposium on ALS/MND and the accompanying 22nd Annual Meeting of the International Alliance of ALS/MND Associations, for the first time being organized in Belgium.

Twenty-five years ago, the international ALS/MND community joined forces to gather annually and exchange the latest developments in science, care and support for the benefit of ALS/MND patients worldwide. Since then, major progress in all these areas has clearly been made, making us all proud. However, the ultimate goal – finding a cure for ALS/MND – has not yet been achieved, and a lot of effort is still ahead of us.

The 25th International Symposium on ALS/MND is also on the eve of the 20th anniversary of ALS Liga Belgium. Our patient organisation started small, as a self-help group by some Belgian ALS patients and their families. Today, we have built an organisation that deals with all aspects of support for ALS/MND patients, including communicating scientific progress on ALS/MND to our patients in a comprehensive way, accelerating scientific research on ALS/MND by continuous fundraising, lending equipment for mobility and communication, building awareness campaigns and interacting with national and regional policy makers and governmental agencies. We are delighted that, as a result, our not-for-profit organisation operates under the gracious patronage of Her Majesty the Queen of Belgium. For several years we have also, as a member of the International Alliance of ALS/MND Associations, taken responsibility for moving things forward in friendly collaboration with other countries.

Although Belgium is geographically rather small and even subdivided into multiple regions that speak different languages, it harbors a number of internationally-renowned opinion leaders in the field of ALS/MND research and care. We are thankful for the close collaboration with them that makes the 25th International Symposium on ALS/MND in Brussels possible.

I hope you all enjoy your time in Belgium and please contact us if you have any questions.

Hartelijk welkom, Soyez la bienvenue, Herzlich willkommen,

Evy Reviers
CEO, ALS Liga Belgium

Foreword

Welcome to the 25th International Symposium on ALS/MND. Recently, a wealth of new data on the genetics and biology of motor neuron degeneration has emerged. New avenues for the understanding of its mechanism have been opened. The speakers and presenters at the symposium will add novel data to these exciting new insights, and invited experts will critically address them. Increasing our knowledge of the biology of this disease will allow us to identify targets for intervention and opens perspectives for novel therapies and therapeutic approaches.

Providing optimal care for ALS/MND patients and their families is the main goal of ALS/MND associations and alliances. Critical evaluation of the treatments and approaches available is necessary to optimally contribute to the improvement of the quality of life of ALS patients and their caregivers. New developments in treatment of ALS patients, and novel ideas on how to approach ALS/MND and ALS/MND patients, will be presented.

This meeting hopes to contribute to a pathway to cure and care. The contribution from all of you is necessary for this. We are looking forward to a meeting that will bring us closer to our common goal.

Wim Robberecht
Programme Committee Chair
Friday 5 December 2014

SESSION 1  
**JOINT OPENING SESSION**  
**Chairs:**  
W Robberecht (Belgium) S Light (UK)  

09.00 – 09.05 Welcome – W Robberecht (Belgium) and S Light (UK)  
09.05 – 09.20 Welcome – Jo Vandeurzen, Minister of Welfare and Public Health (Belgium)  
09.20 – 09.55 What is needed to advance a drug candidate into clinic trials? The perspective of one biotech company – A Sandrock (USA)  
09.55 – 10.05 International Alliance Humanitarian Award  
10.05 – 10.30 IPG Award and winner’s research presentation

10.30 – 11.00 COFFEE

SESSION 2A  
**RNA PROCESSING & DYSREGULATION**  
**Chairs:**  
C Shaw (UK) M Strong (USA)  

11.00 – 11.30 Repeat associated non-ATG (RAN) translation in neurodegenerative disease – L Ranum (USA)  
11.30 – 11.50 Antisense and sense RNA foci derived from repeat expansions of C9orf72 have similar interactions but distinct expression patterns – J Cooper-Knock (UK)  
11.50 – 12.10 C9orf72 expression in amyotrophic lateral sclerosis and frontotemporal dementia – L De Muynck (Belgium)  
12.10 – 12.30 Hexanucleotide repeat expansions cause aberrant intron 1 retention in C9orf72 transcripts: an early event in the pathogenesis of C9ALS/FTD – M Niblock (UK)

SESSION 2B  
**DIAGNOSIS/PROGNOSIS**  
**Chairs:**  
M Turner (UK) M Benatar (USA)  

11.00 – 11.30 The challenge of early therapeutic intervention in ALS – M Benatar (USA)  
11.30 – 12.00 What does the study of premanifest disease contribute? Lessons from other neurodegenerative diseases – S Tabrizi (UK)  
12.00 – 12.20 Cortical excitability in familial C9orf72 ALS patients – N Geevasinga (Australia)  
12.20 – 12.40 Evaluation of routine laboratory tests as possible biomarkers of ALS in the preclinical and clinical phase – V Drory (Israel)

12.30 – 14.00 LUNCH

SESSION 3A  
**PROTEIN MISFOLDING AND TOXICITY**  
**Chairs:**  
L Hayward (USA) V Buchman (UK)  

14.00 – 14.30 The dynamics of protein folding: Pathologic aggregation in ALS mice follows test-tube behaviour – M Oliveberg (Sweden)  
14.30 – 14.50 Misfolded wild-type SOD1 induced by pathological FUS or TDP-43 transmits intercellularly and is propagated misfolding-competent – E Tokuda (Canada)  
14.50 – 15.10 Co-expression of strain A- and B-aggregate forming human SOD1 mutants in mice: studies of aggregate structure and disease phenotype – E Tokuda (Sweden)  
15.10 – 15.30 Glutamate stimulates motor neurons to form intracellular p-TDP-43 aggregates – N Shibata (Japan)

SESSION 3B  
**TRIALS AND TRIAL DESIGN**  
**Chairs:**  
M Cudkowicz (USA) PN Leigh (UK)  

14.00 – 14.20 Does a placebo controlled clinical trial correctly estimate the treatment effect if the delivery method for the treatment and the placebo is potentially harmful? – D Schoenfeld (USA)  
14.20 – 14.40 Intracerebroventricular delivery of VEGF is feasible and safe in patients with amyotrophic lateral sclerosis, a phase I study – P Van Damme (Belgium)  
14.40 – 15.00 The effects of Tirasemtiv on measures of respiratory function in amyotrophic lateral sclerosis (ALS) – J Andrews (USA)  
15.00 – 15.20 Inflammation-associated plasma factors are associated with clinical response to NP001: a post hoc analysis of phase II clinical and laboratory data – M McGrath (USA)

15.30 – 16.00 COFFEE
SESSION 4A  Location: Gold Hall

AUTOPHAGY

Chairs: J Atkin (Australia) S Hadano (Japan)

16.00 – 16.20 P62/SQSTM1 deficiency accelerates motor neuron degeneration in SOD1H46R transgenic mice – S Hadano (Japan)

16.20 – 16.40 C9orf72 interacts with FIP200 and regulates the initiation of autophagy – C Webster (UK)

16.40 – 17.00 Increasing mTOR-independent autophagy enhances disease progression in a mouse model of ALS – N Perera (Australia)

17.00 – 17.20 Rab1 rescues ER stress, macroautophagy and inhibition of ER-Golgi transport induced by mutant FUS in amyotrophic lateral sclerosis – K Y Soo (Australia)

SESSION 4B  Location: Copper Hall

ASSISTIVE TECHNOLOGY

Chairs: S Petri (Germany) C McDermott (UK)

16.00 – 16.30 AAC: from low to high tech – A Reeves (UK)

16.30 – 17.00 Use of brain computer interfaces in ALS – A Kubler (Germany)

17.00 – 17.20 Voice banking and voice reconstruction for MND patients – P Rewaj (UK)

POSTER SESSION A

17.30 – 19.30 Location: Grand Hall 1

17.30 – 18.00 Theme 12A: Scientific work in progress

17.30 – 18.00 Theme 12B: Clinical work in progress and care practice

18.00 – 18.30 Theme 1: Improving diagnosis, prognosis and disease progression

18.00 – 18.30 Theme 6: Epidemiology

18.30 – 19.00 Theme 2: Imaging, electrophysiology and markers of disease progression

18.30 – 19.00 Theme 8: Human cell biology

19.00 – 19.30 Theme 3: Cognitive and psychological assessment and support

19.00 – 19.30 Theme 9: In vitro experimental models

Saturday 6 December 2014

SESSION 5A  Location: Gold Hall

IN VITRO MODELLING

Chairs: M Wiedau-Pazos (USA) K Eggan (USA)

08.30 – 09.00 Are iPSCs living up to their promise? – K Eggan (USA)

09.00 – 09.20 A functional characterisation of C9orf72 iPSC-derived motor neurons – R Mutihac (UK)

09.20 – 09.40 The role of RBM45 in antioxidant responses in ALS – N Bakkar (USA)

09.40 – 10.00 Hexanucleotide repeat expansions in C9orf72 induce nucleolar stress and DNA damage in neuronal cell lines – M Farg (Australia)

SESSION 5B  Location: Copper Hall

CARE PRACTICE

Chairs: H Mitsumoto (USA) T Meyer (USA)

08.30 – 09.00 The role of eHealth in ALS: the Digital Agenda – T Meyer (Germany)

09.00 – 09.20 The impact of neck weakness and experiences of using neck orthoses in people with motor neurone disease – C McDermott (UK)

09.20 – 09.40 A description of pain in ALS – Z Simmons (USA)

09.40 – 10.00 Advance care planning in a Dutch tertiary ALS center, an evaluation of a Dutch care approach – A Seeber (Netherlands)

10.00 – 10.30 COFFEE  Location: Magritte Foyer
<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION A</th>
<th>SESSION B</th>
<th>SESSION C</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 11.00</td>
<td><strong>CELL BIOLOGY AND PATHOLOGY</strong></td>
<td><strong>EPIDEMIOLOGY</strong></td>
<td><strong>BIOMARKERS (I)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Location: Gold Hall</strong></td>
<td><strong>Location: Copper Hall</strong></td>
<td><strong>Location: Silver Hall</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> P Shaw (UK) F Baralle (Italy)</td>
<td><strong>Chairs:</strong> A Chio (Italy) L Cui (China)</td>
<td><strong>Chairs:</strong> A Ludolph (Germany) A Sherman (USA)</td>
</tr>
<tr>
<td>10.30 – 11.00</td>
<td>Functional and structural characterization of the hnRNP TDP 43 and its interactions – F Baralle (Italy)</td>
<td>10.30 – 11.00 Genetics and phenotypes of amyotrophic lateral sclerosis in mainland China – C Lying (China)</td>
<td>14.00 – 14.15 Neurofilament light chain in blood is a prognostic, and a potential pharmacodynamic biomarker for amyotrophic lateral sclerosis – A Malaspsina (UK)</td>
</tr>
<tr>
<td>11.00 – 11.20</td>
<td>Futsch/MAP1B is a translational target of TDP-43 and mitigates toxicity in motor neurons – D Zarnescu (USA)</td>
<td>11.00 – 11.20 Military service and amyotrophic lateral sclerosis in a population-based cohort – M Weisskopf (USA)</td>
<td>14.15 – 14.30 CSF neurofilament light chain concentration reflects corticospinal tract microstructure in ALS – M Turner (UK)</td>
</tr>
<tr>
<td>11.20 – 11.40</td>
<td>Isoform-specific antibodies reveal region-dependent changes in C9orf72 protein levels in brains from ALS cases with repeat expansions in C9orf72 – P McGoldrick (Canada)</td>
<td>11.20 – 11.40 Association between premorbid diabetes mellitus and risk of amyotrophic lateral sclerosis in the Swedish population – D Mariosa (Sweden)</td>
<td>14.30 – 14.50 Multi-center validation of a diagnostic assay for ALS – R Bowser (USA)</td>
</tr>
<tr>
<td>11.40 – 12.00</td>
<td>C9orf72 expansions are potentially pathogenic on three biological levels – S Boeynaems (Belgium)</td>
<td>11.40 – 12.00 Head injury does not alter disease progression or neuropathologic outcomes in amyotrophic lateral sclerosis (ALS) – C Fournier (USA)</td>
<td>14.50 – 15.10 Evaluation of oxidative stress and other biomarkers at the baseline of a large ALS cohort study (ALS COSMOS) – H Mitsuomoto (USA)</td>
</tr>
<tr>
<td>12.00 – 12.20</td>
<td>RNA-dependent and RNA-independent aggregation of FUS in the cell cytoplasm: what structures become precursors of pathological inclusions in FUSopathies? – V Buchman (UK)</td>
<td>12.00 – 12.20 Predicting prognosis in ALS: A simple algorithm – M Elamin (Ireland)</td>
<td>15.10 – 15.30 The role of albumin and creatinine in a population-based cohort of ALS patients – A Calvo (Italy)</td>
</tr>
<tr>
<td>12.20 – 12.40</td>
<td>ELP3 as a disease modifier in ALS – A Bento-Abreu (Belgium)</td>
<td>12.20 – 12.40 Validation of a simple survival score for patients with ALS (ALS-SS) – C Lunetta (Italy)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30 – 14.00</td>
<td><strong>LUNCH</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Location: Grand Hall 2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00 – 14.30</td>
<td><strong>GENETICS AND GENOMICS</strong></td>
<td><strong>END OF LIFE DECISIONS</strong></td>
<td><strong>Biomarkers (I)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Location: Gold Hall</strong></td>
<td><strong>Location: Copper Hall</strong></td>
<td><strong>Location: Silver Hall</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> J Veldink (Netherlands) G Nicholson (Australia)</td>
<td><strong>Chairs:</strong> G Borasio (Italy) J Rosenfeld (USA)</td>
<td><strong>Chairs:</strong> A Ludolph (Germany) A Sherman (USA)</td>
</tr>
<tr>
<td>14.00 – 14.30</td>
<td>Finding ALS genes by means other than linkage – J Hardy (UK)</td>
<td>14.00 – 15.00 Assisted dying in ALS in the Netherlands and Belgium – L van den Berg (Netherlands)</td>
<td>14.00 – 14.15 Neurofilament light chain in blood is a prognostic, and a potential pharmacodynamic biomarker for amyotrophic lateral sclerosis – A Malaspsina (UK)</td>
</tr>
<tr>
<td>15.10 – 15.30</td>
<td>Exome sequencing identifies Matrin 3 as a new ALS gene – J Johnson (USA)</td>
<td>15.00 – 15.30 Discussion</td>
<td>14.50 – 15.10 Evaluation of oxidative stress and other biomarkers at the baseline of a large ALS cohort study (ALS COSMOS) – H Mitsuomoto (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>15.10 – 15.30 The role of albumin and creatinine in a population-based cohort of ALS patients – A Calvo (Italy)</td>
</tr>
</tbody>
</table>
SESSION 8A
Location: Gold Hall

MURINE MODELS
Chairs: L Greensmith (UK) B Turner (Australia)

16.00 – 16.20 Development of mouse model for a newly discovered mutant profilin1 in fALS patients – M Kiaei (USA)

16.20 – 16.40 RNA processing alterations from ALS-linked mutations in FUS/TLS – S Da Cruz (USA)

16.40 – 17.00 Establishing a novel ALS knock-in mouse model with the ALS 8 mutation – P Gaub (Canada)

17.00 – 17.20 Physiological levels of gene expression in a BAC model of TDP-43-associated ALS lead to age dependent motor defects and cytoplasmic redistribution of TDP-43 – D Gordon (UK)

17.20 – 17.40 Transplant of light-sensitive stem cell-derived motor neurons to artificially restore muscle function in the SOD1G93A mouse model of ALS/MND – B Bryson (UK)

SESSION 8B
Location: Copper Hall

RESPIRATORY MANAGEMENT
Chairs: R Miller (USA) G Mora (Italy)

16.00 – 16.20 Screening for respiratory failure in ALS using clinical questioning, respiratory function tests and transcutaneous carbon dioxide: which is the better tool? – M Rafiq (UK)

16.20 – 16.40 Independent factors associated with failed use of noninvasive ventilation (NIV) in patients with ALS/MND – P Cazzolli (USA)

16.40 – 17.00 Further analysis: diaphragm pacing in amyotrophic lateral sclerosis patients with chronic hypoventilation – J Katz (USA)

17.00 – 17.20 Palliative therapy during withdrawal of ventilation – a retrospective analysis of a 10 years experience in ALS – T Meyer (Germany)

17.20 – 17.40 Withdrawal of ventilation at the request of a patient with MND: exploring experiences of those involved – C Faull (UK)

SESSION 8C
Location: Silver Hall

BIOMARKERS (II)
Chairs: M Weber (Switzerland) M Kiernan (Australia)

16.00 – 16.20 Phenotypic characterization and prediction of disease progression in ALS patients by metabolomics approach – H Blasco (France)

16.20 – 16.40 Smads as muscle biomarkers in amyotrophic lateral sclerosis – P King (USA)

16.40 – 17.00 Motor unit number index (MUNIX): ready for clinical ALS trials – a 15 months longitudinal multicentre trial – C Neuwirth (Switzerland)

17.00 – 17.20 Diagnostic utility of threshold tracking transcranial magnetic stimulation in ALS – STARD study – N Geevasinga (Australia)

17.20 – 17.40 Structural connectome analysis in ALS at multicenter level: a controlled study in 200 patients – H Müller (Germany)

POSTER SESSION B
Location: Grand Hall 1

17.45 – 19.30
17.45 – 18.20 Theme 4: Respiratory and nutritional management
17.45 – 18.20 Theme 10: In vivo experimental models
18.20 – 18.55 Theme 7: Genetics
18.20 – 18.55 Theme 11: Therapeutic strategies
18.55 – 19.30 Theme 5: Multidisciplinary care and quality of life
### Sunday 7 December 2014

#### Location: Gold Hall

**SESSION 9A MODULATING SOD1 TOXICITY**

**Chairs:** C Bendotti (Italy) H Durham (Canada)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 08.50</td>
<td>Treatment for amyotrophic lateral sclerosis using AAV9 encoding a microRNA against SOD1</td>
<td>L Stoica (USA)</td>
</tr>
<tr>
<td>08.50 – 09.10</td>
<td>Novel in vivo active synthetic chemical chaperones as a new basis for ALS treatment</td>
<td>A Gruzman (Israel)</td>
</tr>
<tr>
<td>09.10 – 09.30</td>
<td>Cu-ATSM: An effective treatment for high-expressing G93A-SOD1 mice expressing the human Copper Chaperone for SOD1 (CCS)</td>
<td>J Beckman (USA)</td>
</tr>
<tr>
<td>09.30 – 09.50</td>
<td>Small molecules that block propagation of SOD1 misfolding in living cells</td>
<td>L Grad (Canada)</td>
</tr>
</tbody>
</table>

#### Location: Copper Hall

**SESSION 9B NUTRITIONAL ASSESSMENT AND MANAGEMENT**

**Chairs:** V Drory (Israel) E Kasarskis (USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 08.50</td>
<td>Nutrition and functional assessment in ALS patients</td>
<td>C Gennings (USA)</td>
</tr>
<tr>
<td>08.50 – 09.10</td>
<td>A prospective multi-centre evaluation of gastroscopy in patients with MND</td>
<td>T Stavroulakis (UK)</td>
</tr>
<tr>
<td>09.10 – 09.30</td>
<td>Utility of self-report patient scales in the evaluation of dysphagia in individuals with ALS</td>
<td>E Plowman (USA)</td>
</tr>
</tbody>
</table>

---

**10.00 – 10.30 COFFEE**

**Location: Magritte Foyer**

---

#### Location: Gold Hall

**SESSION 10A NON NEURONAL CELLS**

**Chairs:** L Van Den Bosch (Belgium) V H Perry (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 11.10</td>
<td>The contribution of local and systemic inflammation to neurodegeneration</td>
<td>V H Perry (UK)</td>
</tr>
<tr>
<td>11.10 – 11.30</td>
<td>Contribution of CCL2/CCR2 axis in motor neuronal pathology of amyotrophic lateral sclerosis (ALS)</td>
<td>C Bendotti (Italy)</td>
</tr>
<tr>
<td>11.30 – 11.50</td>
<td>Characterization of innate and adaptive immune responses in the hSOD1G93A-MCP1-CCR2 triple transgenic ALS mouse</td>
<td>H Ozdinler (USA)</td>
</tr>
<tr>
<td>11.50 – 12.10</td>
<td>Increased in vivo glial activation in people with amyotrophic lateral sclerosis (ALS)</td>
<td>N Atassi (USA)</td>
</tr>
<tr>
<td>12.10 – 12.30</td>
<td>Oligodendrocytes dysfunction in amyotrophic lateral sclerosis (ALS)</td>
<td>J Leung (Australia)</td>
</tr>
</tbody>
</table>

#### Location: Copper Hall

**SESSION 10B COGNITIVE CHANGE**

**Chairs:** S Abrahams (UK) O Hardiman (Ireland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 11.00</td>
<td>Is ALS-FTD the same as FTD?</td>
<td>J Snowden (UK)</td>
</tr>
<tr>
<td>11.00 – 11.20</td>
<td>The medical decision-making capacity in patients with amyotrophic lateral sclerosis</td>
<td>R Spartaro (Italy)</td>
</tr>
<tr>
<td>11.20 – 11.40</td>
<td>Longitudinal cognitive and behavioural screening in a large US cohort: Results from the COSMOS study group</td>
<td>S Woolley (USA)</td>
</tr>
<tr>
<td>11.40 – 12.00</td>
<td>Multi-dimensional apathy in amyotrophic lateral sclerosis</td>
<td>R Radakovic (UK)</td>
</tr>
<tr>
<td>12.00 – 12.20</td>
<td>Cognitive impairment and behavioural changes are associated with poor survival in ALS</td>
<td>R Govaarts (Netherlands)</td>
</tr>
<tr>
<td>12.20 – 12.40</td>
<td>Prevalence, associations and course of depression in ALS: observations from a large cohort</td>
<td>N Thakore (USA)</td>
</tr>
</tbody>
</table>

---

**12.30 – 14.00 LUNCH**

**Location: Grand Hall 2**

---

#### Location: Gold Hall

**SESSION 11 JOINT CLOSING SESSION**

**Chairs:** W Robberecht (Belgium) K Talbot (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.05</td>
<td>Invitation to Orlando 2015</td>
</tr>
<tr>
<td>14.05 – 14.10</td>
<td>Poster Prize presentation</td>
</tr>
<tr>
<td>14.10 – 14.20</td>
<td>Late breaking news</td>
</tr>
<tr>
<td>14.20 – 15.00</td>
<td>Highlights of 2014</td>
</tr>
</tbody>
</table>

- Basic Research – L Van Den Bosch (Belgium)
- Clinical and Care Management Research – J Ravits (USA)
**Theme 1 Improving Diagnosis, Prognosis and Disease Progression**

**P01 RED FLAGS FOR MUSCLE WEAKNESS: EXPLORING GP DECISION-MAKING AND REFERRAL PATHWAYS**
MCDERMOTT CJ, BAXTER S, BEDFORD J

**P02 FOUNDATION OF THE NETHERLANDS ALS CENTRE IN 2003: REDUCING THE DIAGNOSTIC DELAY**
VISER AE, SELEN M, VELDINK JH, VAN DEN BERG LH

**P03 EXTENDING THE PHENOTYPE OF FOSM N SYNDROME: AN IMPORTANT ALS MIMIC**
BROAD R, LIGHTBODY BJ

**P04 SPORADIC LOWER MOTOR NEURON DISEASE WITH A SNAKE EYES APPEARANCE ON THE CERVICAL ANTERIOR HORMS BY MRI: A NEW CLINICAL SUBTYPE?**
SAHAI S

**P05 AMOTROPHIC LATERAL SCHLOROSIS (ALS) WITH LABORATORY ABNORMALITIES OF UNKNOWN SIGNIFICANCE (LAUS) -- WHERE DOES IT BEGIN AND WHERE DOES IT END?**
BROOKS JR, BRAVERER EK, DESAI UG, STORY SJ, LINDBLOM SC, PACCOCCO TJ, BOCKENEX WL, SANJAK MS, WARD AL, WRIGHT KA, LANGFORD VL, HOLTSEN SE, FISCHER MP, LARY C, NEMETH J, BELCHER SJ, NICHOLS MS, SMITH NP, LUCAS NM, OPLINGER H

**P06 PARANOPLASTIC SUBACUTE LOWER MOTOR NEURON SYNDROME ASSOCIATED WITH SOLID CANCER**

**P16 A DESCRIPTION OF PHYSICIAN PAIN MANAGEMENT PRACTICE IN ALS**
SIMMONS Z, WALSH S, STEPHENS H

**P17 SELF-REPORTED MEASURES PREDICT SURVIVAL IN ALS**
THAOIRE N, PIORO E

**P18 BIOLOGICAL MARKERS FOLLOW UP IN AMOTROPHIC LATERAL SCHLOROSIS: CRREATINE DECREASE AND FERRITIN INCREASE ARE PREDICTIVE OF A PROOF PROGRESSION**

**P19 WHAT DO ALS PATIENTS DIE OF? AN AUTOPSY STUDY OF 70 ALS PATIENTS**
BARKHARD C, NEURWIT C, SOMMACAL A, ANDERSEN P, WEBER M

**P20 MUSCLE ARCHITECTURE BY MEANS OF ELECTROMYOGRAPHY, MULTIFREQUENCY ELECTRICAL IMPEDANCE MYOGRAPHY (MEM) AND FORCE-TIME CURVE (F-TC) ANALYSIS IN ALS PATIENTS AS BIOMARKERS FOR PREDICTING MUSCLE DISEASE PROGRESSION**
CORMA W, CORGANNOI P, TOSI C, DERAMO R, ROSSI B, DINI M

**P21 VIBRATION-INDUCED INHIBITION OF H-REFLEX IN ALS – A BIOMARKER FOR UPPER MOTOR NEURON DYSFUNCTION AND PREDICTOR OF FUNCTIONAL IMPAIRMENT**
LEE M, LANCE J, BURKE D, CHAMPATAY T, SCHOLTZ D, ANDERSON P, BENATAR M

**P22 EVIDENCE FOR PERIPHERAL IMMUNE ACTIVATION IN AMOTROPHIC LATERAL SCHLOROSIS**
CHEN X, GUIO X, CHEN Y, SHANG H

**P23 URINARY P75 NEUROTROPHIN RECEPTOR EXTRACELLULAR DOMAIN AS A BIOMARKER OF SYMPTOMATIC DISEASE ONSET AND PROGRESSION**
ROGERS M-L, WUU J, SHEPHEARD S, CHATAWAY T, SCHULTZ D, ANDERSON P, BENATAR M

**P24 CORTICAL ATROPHY IN THE ALS-FTD SPECTRUM**
RATTI E, DOMOTO-REILLY K, HOCHEBERG D, BRICKHOUSE M, CASO C, MURPHY C, CUDKOWICZ M, DICKESSON B

**P25 PATTERNS OF CEREBRAL AND CEREBELLAR WHITE MATTER DEGENERATION IN ALS**

**P26 SUBCORTICAL STRUCTURES IN AMOTROPHIC LATERAL SCHLOROSIS**
WESTENH J, VERSTRAETE E, WALHOUT R, KENNA K, VAJDA A, FARGAN A, BRADLEY D, HARDIMAN O

**P27 THE SPECTRUM OF BASAL GANGLIA PATHOLOGY ACROSS THE ALS-FTD CONTINUUM**
MACHTJ C, LOEWE K, BYRNE M, SCLAUFSLINH R, KENNA K, VAJDA A, FARGAN A, BRADLEY D, HARDIMAN O

**P28 MICROSTRUCTURAL CHANGES ACROSS DIFFERENT STAGES OF DISEASE IN AMOTROPHIC LATERAL SCHLOROSIS**

**P29 FUNCTIONAL CONNECTIVITY HALLMARKS IN ALS**
LOEWE K, MACHTJ C, STOPPEL C, KIERNAN MC, SCHULZ Dt, HOPF H, BRETTSCHEIDER J, DEL TREDICI K, BRAHAK H, LUDOLPH AC, KASSUBEK J

**P30 IN VIVO TRANSFER OF PATHOLOGY SPREADING PATTERNS BY DTI ANALYSIS IN ALS**
KABRIUB J, MOLLER HANS-P, VELDING E, BÖHM L, BÖYKH H, LUDOLPH AC, KASSUBEK J
P84 NON-INVASIVE VENTILATION INFLUENCES RESTING ENERGY EXPENDITURE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS
MARINOU K, Bowed G, Cena H, Manari P, Mora G
P85 EFFECTS OF EARLY NON INVASIVE VENTILATION ON PULMONARY FUNCTION IN ALS PATIENTS: PRELIMINARY RESULTS OF A RANDOMIZED CONTROL TRIAL
P86 SAFETY AND TOLERABILITY OF SYSTEMIC BETARE-ADRENERGIC AGONIST (ALBUTEROL) AS PHARMACOLOGICAL THERAPY IN NON-INVASIVE VENTILATION (NIV)-SUPPORTED AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS WITH CHRONIC RESPIRATORY FAILURE
P87 TIMING OF INTRODUCTION OF NONINVASIVE VENTILATION AND MECHANICALLY ASSISTED COUGHING IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS
P88 EVALUATION OF THE COUGHASSIST E70 COMPARED TO COUGHASSIST 3000 IN ADULTS WITH AMYOTROPHIC LATERAL SCLEROSIS
Jordi C, Lotz G, Jasko J, Boyce C, Schacht M, Jackson L, Kittrell P
P89 SLEEP QUALITY AND PATIENT-PHANTOM ASYNCHRONY DURING NONINVASIVE VENTILATION IN AMYOTROPHIC LATERAL SCLEROSIS
Vrijsen B, Buyse B, Belge C, Van Damme P, Testelmann D
P90 TRACHEOSTOMY AND INVASIVE VENTILATION IN JAPANESE ALS PATIENTS: DIFFERENCES IN MAKING AND SURVIVAL ANALYSIS
Kimura F, Tagami M, Ota S, Tukahara A
P91 AN UPDATE ON OPINIONS AND BEHAVIORS OF JAPANESE AND AMERICAN ALS CAREGIVERS REGARDING TRACHEOSTOMY WITH INVASIVE VENTILATION (IVV)
Christodoulou G, Ogino M, Goetz R, Mitsumoto H, Rabkin J, American and Japanese TV study group
P92 COMPARISON OF COMMUNICATION ABILITY STAGE WITH ADVERSE CLINICAL SIGNS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) ON TRACHEOSTOMY INVASIVE VENTILATION (TIV)

Theme 5 Multidisciplinary Care and Quality of Life
P93 DIAPHRAGM PACING REFEREAL PATHWAY AND OUTCOMES IN AN ACADEMIC MULTIDISCIPLINARY ALS CLINIC
Raheja D, Walsh S, Stephens H, Simmons Z
P94 ASSESSMENT OF BULBAR FUNCTION IN ALS
Smith RA, Pattee G, Pioro E, Schoenfeld D
P95 5% SCOPOLAMINE OINTMENT IS CLASSICAL BUT STILL USEFUL FOR ALS AND OTHER NEUROLOGICAL DISEASES
Nagashima K, Ogino M, Tominaga N, Uchino A, Ogino Y, Nishiyama K
P96 AFFECTS OF DYSPHAGIA AND GASTROSTOMY FEEDING ON QUALITY OF LIFE
FOR PEOPLE WITH MOTOR NEURODE NEURODISEASE DOYLE E, Mcellignott K, Hardiman O
P97 ALS SYMPTOMS, DISABILITY AND QUALITY OF LIFE: LITERATURE REVIEW AND MODEL GENERATION
Young C, Ainsley G
P98 THE RELATIONSHIP BETWEEN DYSARTHRIA AND QUALITY OF LIFE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Ferdoli S, Ginciochchi D, Lunetta C, Sansone V, Schindler F
P99 LIMITING CONDUCTIVE-SENSONEURAL HEARING LOSS IN PATIENTS WITH ADVANCED AMYOTROPHIC LATERAL SCLEROSIS
Ginocchio D, Barozzi S, Maestri E, Corbo M, Sansone V, Lunetta C
P100 AMYOTROPHIC LATERAL SCLEROSIS AND PAIN
Idrisoglu HA, Polat N, Idrisoglu M
P101 PAIN ASSESSMENTS IN A MULTINATIONAL SAMPLE
Stephens H, Walsh S, Simmons Z
P102 SELF-PERCEIVED EXPERIENCES OF PAIN IN ALS/MND
Akermeyjlo M, Zetterberg L, Jakobsson LB, Aslenp L
P103 MORPHINE USE IN ALS PATIENTS ON NPPV DOES NOT MAKE LIFE EXPECTANCY WORSE
P104 PREVALENCE OF BOWEL AND BLADDER SYMPTOMS ATTRIBUTABLE TO ALS
P105 THE PATIENT EXPERIENCE OF SPASTICITY IN MOTOR NEURODE NEURODISEASE
Munin K, Young C, On behalf of the tonic study group
P106 SELF-ASSESSMENT OF PHYSICAL THERAPY IN ALS
P107 HOW STORIES COMMUNICATE DAILY LIVING WITH ALS
Jeppesen J, Rahbek J, Gradel O, Ploog HH
P108 PATIENT COMMUNICATION AND TREATMENT PREFERENCES IN AN ALS CLINIC
Van de Walle S, Stephens H, Simmons Z
P109 A QUALITATIVE STUDY TO CONSTRUCT A PREDICTIVE SCALE FOR PEOPLE WITH AMYOTROPHIC LATERAL SCLEROSIS
Nakay A, Narita Y
P110 ANALYSIS OF DEPRESSION AND ANXIETY IN ALS PATIENTS
Tejado DA, Perez JS, Moreno MJ, Turon SJ, Povedano PM, Paipa MA, Laaz LA, Toti C
P111 ILLNESS REPRESENTATIONS AND COPING STRATEGIES AS DETERMINANTS OF QUALITY OF LIFE IN AMYOTROPHIC LATERAL SCLEROSIS: FINDINGS FROM A GREEK SAMPLE
P112 COGNITIVE CHANGE AND QUALITY OF LIFE IN AMYOTROPHIC LATERAL SCLEROSIS
Niven E, Kavanagh J, Bick J, Stephens H, Simmons Z, Abrahams Z
P113 WHAT IS UNIQUE ABOUT QUALITY OF LIFE IN MOTOR NEURODE NEURODISEASE?: A QUALITATIVE QUERY
Young C, Ando H, Cousins R
P114 THE DEVELOPMENT OF A CONSENSUS PAPER ON PALLITIVE CARE IN NEUROLOGY – THE IMPLICATIONS FOR ALS CARE
Oliver D, Borsai DO, Volitz R, Caraceni A, De Vissier M, Lorenzl S, Veronesi S, Grisold W
P115 END OF LIFE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS): A REVIEW
Conolly S, Galvin M, Hardiman O
P116 ETHICAL ASPECTS TO CONSIDER IN COUNSELLING FOR END-OF-LIFE DECISION MAKING
P117 ASSISTIVE DEVICES IN ALS – ANALYSIS OF 3 YEARS OF MANAGED CARE
P118 EQUIPMENT UTILIZATION IN THE ALS/MND POPULATION – TRENDS AND TIMING
Allred P, Feldman S
P119 DEVELOPMENT OF A POWERED ‘NEURO’ WHEELCHAIR PRESCRIPTION TOOL
P120 EVALUATION OF CURRENTLY AVAILABLE NECK COLLARS FOR COMFORT AND IMPACT ON ACTIVITIES OF DAILY LIVING
Langley J, Reed H, Stanton A, Heron N, Clarke J, Judge S, Shaw PJ, Quinn A, McDermott CJ
P121 HEAD UP: CO-DESIGNING A NOVEL CERVICAL ORTHOSIS FOR MND PATIENTS
Reed H, Stanton A, Langley J, Shaw PJ, Heron N, Quinn A, McDermott CJ
P122 NEW DISEASE MANAGEMENT TOOLS – CERNM ELECTRONIC MEDICAL RECORD DEPLOYMENT OF AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE-REVISED (ALS FRS-R) VALIDATED WITH MOBILE SMARTPHONE (IPHONE/ANDROID) APPLICATION (ALSFRS-R-LITE)
P123 UNDERSTANDING PSYCHO-SOCIAL PROCESSES THAT UNDERPIN HOW PEOPLE WITH ALS MAKE DECISIONS ABOUT CARE
Foley G, Timonen V, Hardiman O
P124 DISCRETE CHOICE EXPERIMENT FOR PREFERENCES OF CARE IN MOTOR NEURODE NEURODISEASE PATIENTS AND THEIR CAREGIVERS
Maguire S, Tobin K, Normand C, Hardiman O
P125 SOUTH WALES MOTOR NEURODE NEURODISEASE CARE NETWORK – AN AUDIT OF CARE PROVISION IN SOUTH WALES
Glew R, Hancock K, Baker I, Dawson K, Hadjikouts S
P126 VISION FOR THE FUTURE – THE NETWORK APPROACH: A NEW MODEL FOR CARE PROVISION FOR PEOPLE WITH MOTOR NEURODE NEURODISEASE (MNND) – SOUTH WALES MND CARE NETWORK
P127 VALIDATION OF A NURSING CONTINUING EDUCATION PROGRAM FOR THE CARE OF PATIENTS WITH INTRACTABLE NEUROLOGICAL DISEASE, WITH AN EMPHASIS ON ACTIVE LISTENING
P128 THE SCOTTISH MOTOR NEURODE NEURODISEASE AUDIT, RESEARCH AND TRIALS (SMART) STUDY: AN AUDIT OF THE HEALTH CARE OF PEOPLE WITH MND/ALS IN SCOTLAND
P129 Caring experiences of children and adolescents of a family member with ALS
Kavnaugh M, Banker-Horner L, Bahrhaus PE, Under commercial insurance.

P130 Bereavement support needs of family caregivers of people with motor neuron disease (MND)
O’Brian M, Kirkcaldy A, Jack B, Bell S, Knighting K, Roe B

P131 Why/how are families in Japan able to cope with long-term care in spite of the associated burdens?
Kawaguchi Y, Ishijima K, Konagaya M, Nakayama Y

P132 An ambulatory model of medical and social care for MND patients in Russia
Lygosorkesia E, Cherveykovak A, Fominykh V, Ivanova M, Vorobyeva A, Zakharkova M, Breliev L, Balik K, Dikhter E, Fomina KH, Orlova O, Shtabnitsky V, Sonkina A

Theme 6 Epidemiology

P133 Profile of Medical care costs in patients with Amyotrophic lateral sclerosis in Medicare program and under commercial insurance.

P134 The role and view of study coordinators in a multicenter ALS study (ALS Cosmos)

P135 Socioeconomic differences in functional parameters at ALS diagnosis

P136 Factors affecting longitudinal functional decline and survival in Amyotrophic lateral sclerosis patients

P137 Detection of Beta-N-Methylamino-L-Alanine (β-NMA) as a biomarker of Amyotrophic Lateral Sclerosis

P138 Increased tumor necrosis factor-α in the skin of patients with Amyotrophic Lateral Sclerosis, an immunohistochemical study
Fujiura M, Ono S

P139 Were Nutritional factors associated with high incidence of ALS in the K area?
Okamoto K, Kihira T, Kobuku Y, Kuzuhara S

P140 Bmma analysis in the brains of Amyotrophic lateral sclerosis/als/amyotrophic dystrophy complex of the kii peninsula of Japan
Kobuku Y, Banack S, Morimoto S, Murayama Y, Toishig T, Cox PA, Kuzuhara S

P141 Is parental survival associated with the risk of Amyotrophic lateral sclerosis? - exploring the fitness hypothesis
Visser AE, Seelen M, de Graaf JA, Hulsbergen AD, Veldink JH, van den Berg LH

P142 Blood Lead, Bone Turnover, and Survival in Amyotrophic lateral sclerosis

P143 Application of a staging system to the PRODAT database population
Hermann Jetterson T, DeY S, Alexander G, Deboo A

P144 Age-period-cohort analysis of trends in ALS incidence
Tobin K, Hardiman O

P145 Aggregation of Neuropsychiatric disease in amyotrophic lateral sclerosis cochasle of clustering within families
O’Brian M, Heverin M, Byrne S, Elam M, Hardiman O

P146 Cluster analysis of ALS risk in Ireland

P147 Atxniq oq1q5 intermediate repeat is a modifier of ALS phenotype in a population based study

P149 Epidemiology of amyotrophic lateral sclerosis in Israel (1997-2013)
Wolff A, Blumen H, Iwasaki K, Pyenson B

P150 The long saga of a Vcp gene mutation in a large family
Blumenard M, Gonzales-Perez P, Drory V, Brown M, Blumenthal AN

P151 The German pre-symptomatic ALS risk-carrier study (GPS-ALS) 2014

P152 The epidemiology and treatment of amyotrophic lateral sclerosis in Canada: new insights from the canadian neuromuscular disease registry

Mehta P, Horton K, Antov O

P154 amyotrophic lateral sclerosis (ALS) re-admissions at carolina healthcare system - higher than stroke re-admission

P155 Blood levels of trace metals and amyotrophic lateral sclerosis (ALS) in US military veterans

P156 Sod1 gene mutations in ALS patients Turkish population
Irishoglu HA, Polat N, Irishoglu M

P157 Natural history and clinical features of sporadic Amyotrophic lateral sclerosis in China: a ten-year clinical-based cohort study

Theme 7 Genetics

P158 Complete mutational spectrum of known ALS genes in a large cohort of familial ALS cases
Müller K, Marroquin N, Volk AE, Hübbers A, Meyer T, Andersen PM, Mettinger T, Ludolph AC, Strem TM, Weshaupt JH

P159 A Dutch family with autosomal recessive motor neuron disease caused by optineurin mutations
Beeldman E, van Russies F, Baas F, De Visser M, van der Kooi A

P160 Spectrum of mutations in ALS genes on the island of Sardinia

P161 Tar-droptomuto or a distal motor neuronopathy in a sardinian patient
Caldarazzi E, Carlesi C, Lo G, Chico L, Mancuso M, Fogli A, Sini P, Siciliano L

P162 Arghgf28 gene exon 6/Intron 6 junction mutations in Chinese amyotrophic lateral sclerosis cohort
Yang Y, Tang L, Zhang B, Fan D

P163 Five novel Sqt3m1 mutations in a Chinese amyotrophic lateral sclerosis cohort
Yang Y, Tang L, Zhang B, Fan D

P164 Evidence of common genetic variation for ALS risk in Chinese samples

P165 C9orf72 hexanucleotide repeat expansions are rare and hyper-methylated in Chinese sporadic amyotrophic lateral sclerosis

P166 Analysis of C9orf72 repeat expansion in amyotrophic lateral sclerosis patients from southwest China
Shang H, Chen Y, Chen X

P167 A blinded comparative study on the reliability of genetic testing for the ggggcc-repeat expansion in C9orf72 performed in 14 Laboratories
Akimoto C, Volk AE, Nordin A, Andersen PM, Kubisch C

P168 Variation in size of the C9orf72 ggggcc-repete expansion between different tissues in ALS and FTD

P169 Screening for C9orf72 repeat expansion in amyotrophic lateral sclerosis
Moscúl A, Talaríni C, Lunetta C, Sansove N, Pencio S

P170 Identification of new genetic determinants in sporadic ALS
Courtouis J, Raphael A, Gilter A

P171 Investigating the genetic basis of amyotrophic lateral sclerosis using next-generation sequencing techniques

12
**Theme 11 Therapeutic Strategies**

P264 GENE THERAPY FOR SPORADIC ALS USING AN INTRAVENOUS INJECTION OF AAV VECTOR  
YAMASHITA T, CHI JH, TERAMOTO S, MURAMATSU S, IKAWA S

P265 ADENOVIRAL TARGETING OF THE MOTOR END PLATE REGION FOR INCREASED TRANSDUCTION OF MOTOR NEURONS AND SKELETAL MYOFIBRES  
TOSOLINI A, MOHAN R, MORRIS R

P266 SPECIFIC GENE DELIVERY TO CORTICOSPINAL MOTOR NEURONS BY AAV JARA J, STANFORD M, ZHU Y, BOSSARD J, OZOLT M

P268 LIPOSOME-ENCAPSULATED H-FERRITIN  
SSMITH KS, HOFFMAN L, RUSSELL ROBERT A, VOELCKER NE

P267 TARGETED NON-VIRAL GENE DELIVERY TO MOTOR NEURONS AND SKELETAL MYOFIBRES  
JARA J, STANFORD M, ZHU Y, BOHN M, DEVRIES S, CORTICOSPINAL MOTOR NEURONS BY AAV

P265 ADENOVIRAL TARGETING OF THE MOTOR END PLATE REGION FOR INCREASED TRANSDUCTION OF MOTOR NEURONS AND SKELETAL MYOFIBRES

P266 SPECIFIC GENE DELIVERY TO CORTICOSPINAL MOTOR NEURONS BY AAV

P268 LIPOSOME-ENCAPSULATED H-FERRITIN

P267 TARGETED NON-VIRAL GENE DELIVERY TO MOTOR NEURONS AND SKELETAL MYOFIBRES

Theme 12A Scientific Work in Progress

P284 EFFECT OF RILUZOLE TREATMENT ON MOTOR NEURON FUNCTION AND PERFORMANCE IN MOUSE: RESULTS OF A CLINICAL TRIAL

P280 GENDER DIFFERENCES IN EMERGING NEUROGENETIC DISEASES SPINAL MUSCULAR ATROPHY AND AMYOTROPHIC LATERAL SCLEROSIS

P283 RELATIONSHIPS BETWEEN RILUZOLE AND THE MND-ATTENUATING COMPOUND NRF2 PATHWAY IN CULTURED ASTROCYTES

P274 THE MND-ATTENUATING COMPOUND CUI5 (ATSM) ACTIVATES THE ANTI-OXIDANT NDRF2 PATHWAY IN CULTURED Astrocytes

P275 CORRECTING DEFECTIVE ENDOLAMIC RETICULUM-MITOCHONDRIA INTERACTIONS AS A NEW THERAPEUTIC TARGET FOR ALS: CHARACTERISATION OF NOVEL DRUG SCREENS

P276 IMPROVEMENTS IN MOTOR FUNCTION, CA2+ CLEARANCE AND MARKERS OF RETICULUM MITOCHONDRIA INTERACTIONS THROUGH MULTIPLE SIGNALING PATHWAYS

P277 CNS102 IMPROVES SURVIVAL AND MOTOR BEHAVIOUR IN SOD1 MICE AND PROTECTS FROM EXTRACELLULAR TOXICITY

P279 PSYCHOSOCIAL AND PSYCHOTHERAPEUTIC APPROACHES FOR PEOPLE WITH MND: A QUALITATIVE STUDY

P281 IMPLICATIONS OF EXCITATORY MUSCLE STRENGTH TRAINING ON BULBAR FUNCTION IN AMYOTROPHIC LATERAL SCLEROSIS: UPDATES FROM A RANDOMIZED SHAM-CONTROLLED CLINICAL TRIAL

P282 MECHANICAL INSUFFLATION/EXSUFFLATION WITH HIGH FREQUENCY CHEST WALL OSCILLATION: RESULTS OF A CLINICAL TRIAL

P283 RELATIONSHIPS BETWEEN RILUZOLE AND TIRAISEMT LEVELS ON OUTCOMES IN THE BENEFIT-ALS TRIAL


P286 FAST KINETIC MUSCLE TROPHIN ACTIVATOR TIRAISEMT INCREASES MUSCLE FUNCTION AND PERFORMANCE IN MOUSE MODELS OF SPINAL MUSCULAR ATROPHY

P287 DIPS: PATIENT AND CARER EXPERIENCES OF DIAPHRAGM PACING IN MOTOR NEUROGENIC DISEASE.
SW14 CHARACTERISATION OF NEURONS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS FROM MOTOR NEURONE DISEASE PATIENTS IDENTIFIES ALTERATIONS IN PROTEOSTATIC MECHANISMS OOI L, BAX M, BALZER R, DO-HA D

SW15 EARLY DYSFUNCTION AND NON-CELL AUTONOMOUS DISEASE MECHANISMS IN A HUMAN IPSC-BASED MODEL OF ALS DOUIN A-C, ZHAO C, BURK K, CHANDRAR S, MILES G8

SW16 INVESTIGATING THE FUNCTIONAL CONSEQUENCES OF RNA PROCESSING DYSREGULATION IN ALS CELL MODELS DODD J, SHAH PJ, HAUTBERGUE GM

SW17 ESTABLISHING A STABLE CELL MODEL OF C9ORF72-ALS STOPFORD M, HIGGINBOTTOM A, SHAH PJ, KIRBY J

SW18 STUDYING GLIA-NEURAL INTERACTION IN C9ORF72 EXPANSION METASTROPHIC USES AN INDUCES PLURIPOTENT STEM CELL BASED IN VITRO MODEL ZHAO C, THANGARAJ SB, SERIO A, MAGNANI D, BURK K, EVANS L, VASISHTHA N, STORY D, PATANI R, SHAW CE, CHANDRAN S

SW19 INVESTIGATION OF THE ER AND MITOCHONDRIA CALCIUM CYCLE IN THE PRESENCE AND ABSENCE OF HUMAN G93A MUTATED SOD1 TADIC V, PRELL T, LIU C, WITTE OW, GROSSKREUTZ J

SW19.5 IN VITRO ANALYSIS OF GLIAL CELL TOXICITY TO SPINAL CORD MOTOR NEURONS IN THE PRESHYMPOMATOUS PHASE OF SOD1 G93A ALS MOUSE MODEL - A POSSIBLE INVOLVEMENT OF TNFA, IL-6 AND NGF SIGNALLING. CHIZI G, DUOYLES T, SCORISA JM, ALVES CJ, MADOJJE IE

SW20 EXTRACELLULAR AGGREGATED SOD1 IS TOXIC TO ASTROCYTES ROBERTS K, YERBURY J, CAMPBELL IL

SW21 HSOD AND THE ALS ASSOCIATED MUTATION G93A INDUCE SPECIFIC LIPIDOMIC CHANGES IN CENTRAL NERVOUS SYSTEM IN TRANSGENIC MICE JÖVE M, CABACÉLOS D, CACABELOS D, AYALA V, BOADA J, ROBERTS D, PIKE J, MEENERTZ DM

SW22 STEM CELL SURVIVAL IN THE SOD1 RAT MODEL AS A COMPLEMENTARY MEASURE TO FA IN ALS GABEL M, AL-CHALABI A, TSSERTMENTELI S, GOLDSTEIN L, GIULIETTI G, LEIGH PN, SIMMONS A, WILLIAMS AH, WALKER J, M5

SW23 CELLULAR THERAPY OF HUMAN MODEL OF AMYOTROPHIC LATERAL SCLEROSIS WITH SPINAL CORD TARGETING PEPTIDES TERSASHIMA T, OGAWA N, URABE H, KAWAI H, KOJIMA H, MAEGAWA H

SW24 NEW MOLECULAR THERAPY FOR AMYOTROPHIC LATERAL SCLEROSIS WITH SPINAL CORD TARGETING PEPTIDES RAYMOHAN T, ODAKU N, UJIKI M, MURAKAMI K, TAKAHASHI K, TAKAHASHI K

SW25 CLINICAL TRIAL OF CETFRIAXONE IN SUBJECTS WITH ALS - POST-HOC ANALYSIS USING CETFRIAXONE CUMULATIVE DOSE BANNO H, BERRY J, HAYDEN D, CUĐOWICZ M

SW26 RILUZOLE AS A RISK FACTOR FOR VTE IN ALS BANGAL S, VRIS S, COLEMAN J

SW27 THE DEVELOPMENT OF MESSAGE BANKING AS A PATIENT-DRIVEN CLINICAL TOOL DOYLE L, JAGOE C

Theme 128 Clinical Work in Progress and Care Practice

CW1 TO DO OR NOT TO DO? ADVISING LEVEL OF ‘DOING’ IN MND CAREY H, ROBERTS D, PIKE J


CW3 NUMBER OF C9ORF72 REPEAT EXPANSIONS AND PHENOTYPIC CORRELATION IN ALS ASSALIOLU A

CW4 MONOCYTE SUBTYPES IN ALS ZÖNLER L, MULLER K, GRODDANOV V, BJÖRDE-LAURSEN C, WEYDT P, LUDOVIC AC, DANZER K, WEHAUPT J, H

CW5 PROTEOMIC ANALYSIS OF MUSCLE TISSUE FROM PATIENTS WITH MOTORNEURON DISEASE AND CONTROLS ELF K, SHEVCHENKO G, NIGRED J, H

CW5.5 CHOLESTEROL METABOLITES REGULATE MOTOR NEURON SURVIVAL VIA LIVER X RECEPTORS GRIFFITHS W, THEOPILOPOULOS S, ARENAS E, WANG Y

CW6 DEVELOPMENT OF A NEW PROTEIN MARKER PANEL USING SELECTION REACTION MONITORING MASS SPECTROMETRY (SRM-MS) ZUBIRI I, WARD A, MANG H-C, LEONI E, LU C-H, GREENSMITH L, PIKE I, MALASPINA A


CW7.5 ANATOMICAL CONNECTIVITY MAPPING AS A COMPLEMENTARY MEASURE TO FA IN ALS CHEONG I, OZ G, MARIJANSA M, LENCLET C, MCKINNEY A, ROLANDELLI S, WALK D

CW8 EFFECTS OF THE ENDOCANNABINOID SYSTEM MODULATION ON EXCITOTOXIC STRESS OF RAT HYPOGLOSAL MOTORNEURONS SERZYSKO-SOSNOWSKA M, NISTRI A

CW10 THRESHOLD TRACKING REVEALS CHANGES OF PERIPHERAL AXONAL EXCITABILITY IN HEREDITARY SPASTIC PARAPLEgia JUNKEL A, PRELL T, WITTE OW, GROSSKREUTZ J


CW13 UPPER MOTOR NEURON DIAPHRAGM PARALYSIS IN AMYOTROPHIC LATERAL SCLEROSIS ROSS M

CW14 OUTCOMES OF AMYOTROPHIC LATERAL SCLEROSIS PATIENTS WITH PERCUTANEOUS ENDOSONIC GASTROTOSTOMY AND INVASIVE VENTILATION (TRACHEOSTOMY) DRISOGLU HA, POLAT N, IDRISOGLU M

CW15 SPEECH AND LANGUAGE THERAPY AS A RESOURCE IN THE CREATION OF PERSONAL LEGACY BOOKS DOYLE L

CW16 TREATMENT OF NEUROGENIC STUTTERING IN MND: A CASE REPORT WEBER V, MASUDA M

CW17 A PILOT STUDY ASSESSING A NEW EYE-WRITING DEVICE ALLOWING CURSIVE WRITING WITH SMOOTH PURSUIT EYE MOVEMENTS IN MODIFIED ALS LENGETT T, VEYRAT-MASSON M, LOURENCHEU J, LACOMBLEZ L, SALACHAS F

CW18 PREVALENCE OF PERIPHERAL ODEMEA IN ALS AND CURRENT TREATMENT GUIDELINES SHAHRABI M, PILOSOFF L

CW19 THE LOST ART OF KISSING SHAHRABI M, CIANCI G, HOBBERG S, LAND D

CW20 EXPLORATION OF CARING EXPERIENCES IN AMYOTROPHIC LATERAL SCLEROSIS: A PRELIMINARY ANALYSIS GALVIN M, CONNOLLY S, MAY S, HARDIMAN O

CW21 CAREGIVER BURDEN IN AMYOTROPHIC LATERAL SCLEROSIS (ALS): A PROSPECTIVE ANALYSIS GALVIN M, CONNOLLY S, MAY S, HARDIMAN O

CW22 PSYCHOLOGICAL PROBLEM OF CHILDREN WITH PARENTS WITH ALS AHN H

CW23 ASSESSING PATIENT COGNITION AND BEHAVIOUR IN SPECIALISED ALS MULTIDISCIPLINARY CARE: A STUDY PROTOCOL WALTON A, CAGA J, GREENFIELD D, MIOSHI E


CW25 CHALLENGES AND REWARDS OF SETTING UP A NETWORK MODEL: SOUTH WALES MOTOR NEURONE DISEASE (MND) CARE NETWORK GLERW R, HANCOCK K, JAMES J, DAWSON K, BAKER I, HADJIKOTIS S

CW26 REVERSING THE HUB AND SPOKE MODEL: PATIENT EXPERIENCES OF THE DEVELOPMENT OF A COMMUNITY BASED MULTI DISCIPLINARY MOTOR NEURONE DISEASE AND CONTROLS MND CLINIC TO MEET THE MOTOR NEURONE DISEASE ASSOCIATION ‘STANDARDS OF CARE’ ATKINSON C, BROWN C, BAKER M

CW27 OCCUPATIONAL THERAPY: MAINTAINING FUNCTION THROUGH THE LIFE SPAN WARD A, WARD A, HOLSTEEN SE

CW28 QUALITY OF LIFE IN AMYOTROPHIC LATERAL SCLEROSIS (ALS): A PRELIMINARY ANALYSIS SODI M, GLERW R, HANCOCK K, JAMES J

CW29 MISCONCEPTIONS IN PALLIATIVE CARE FOR PATIENTS WITH ALS KAPLANI L, SHAHRABI M, KASSEBAUM N, LANGE D, PILOSOFF L

CW30 COLLABORATION BETWEEN ALS AND PALLIATIVE SPECIALISTS IN DENMARK JAKOBSEN S, PUJIC SN, GREDEL O
## Programme of events/locations

### Friday 5 December

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00 – 18.00</td>
<td>Registration International Symposium</td>
<td>Registration Lobby</td>
<td>Level -1</td>
</tr>
<tr>
<td>07.00 – 18.00</td>
<td>Speaker Room</td>
<td>Registration Lobby</td>
<td>Level -1</td>
</tr>
<tr>
<td>07.15 – 08.15</td>
<td>NEALS</td>
<td>Studio 211/212</td>
<td>Level 2</td>
</tr>
<tr>
<td>09.00 – 10.30</td>
<td>Symposium Joint Opening Session</td>
<td>Gold Hall</td>
<td>Level 0</td>
</tr>
<tr>
<td>10.30 / 15.30</td>
<td>Refreshment breaks am/pm</td>
<td>Magritte Foyer</td>
<td>Level 0</td>
</tr>
<tr>
<td>11.00 – 17.20</td>
<td>Symposium Scientific Sessions 2A/3A/4A</td>
<td>Gold Hall</td>
<td>Level 0</td>
</tr>
<tr>
<td>11.00 – 17.20</td>
<td>Symposium Clinical Sessions 2B/3B/4B</td>
<td>Copper Hall</td>
<td>Level 0</td>
</tr>
<tr>
<td>12.30 – 14.00</td>
<td>Lunch</td>
<td>Grand Hall 2</td>
<td>Level -2</td>
</tr>
<tr>
<td>17.30 – 19.30</td>
<td>Poster Session A</td>
<td>Grand Hall 1</td>
<td>Level -2</td>
</tr>
<tr>
<td>17.30 – 19.30</td>
<td>Project MinE (closed meeting)</td>
<td>Studio 201 A/B</td>
<td>Level 2</td>
</tr>
</tbody>
</table>

### Saturday 6 December

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00 – 18.00</td>
<td>Registration International Symposium</td>
<td>Registration Lobby</td>
<td>Level -1</td>
</tr>
<tr>
<td>07.00 – 18.00</td>
<td>Speaker Room</td>
<td>Registration Lobby</td>
<td>Level -1</td>
</tr>
<tr>
<td>08.30 – 17.40</td>
<td>Symposium Scientific Sessions 5A/6A/7A/8A</td>
<td>Gold Hall</td>
<td>Level 0</td>
</tr>
<tr>
<td>08.30 – 17.40</td>
<td>Symposium Clinical Sessions 5B/6B/7B/8B</td>
<td>Copper Hall</td>
<td>Level 0</td>
</tr>
<tr>
<td>14.00 – 17.40</td>
<td>Symposium Alternative Sessions 7C/8C</td>
<td>Silver Hall</td>
<td>Level 0</td>
</tr>
<tr>
<td>10.00 / 15.30</td>
<td>Refreshment breaks am/pm</td>
<td>Magritte Foyer</td>
<td>Level 0</td>
</tr>
<tr>
<td>12.30 – 14.00</td>
<td>Lunch</td>
<td>Grand Hall 2</td>
<td>Level -2</td>
</tr>
<tr>
<td>17.30 – 19.00</td>
<td>Cochrane Neuromuscular Group</td>
<td>Studio 201 A/B</td>
<td>Level 2</td>
</tr>
<tr>
<td>17.45 – 19.30</td>
<td>Poster Session B</td>
<td>Grand Hall 1</td>
<td>Level -2</td>
</tr>
</tbody>
</table>

### Sunday 7 December

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00 – 08.30</td>
<td>WALS</td>
<td>Studio 201 A/B</td>
<td>Level 2</td>
</tr>
<tr>
<td>07.00 – 14.00</td>
<td>Speaker Room</td>
<td>Registration Lobby</td>
<td>Level -1</td>
</tr>
<tr>
<td>07.30 – 13.00</td>
<td>Registration International Symposium</td>
<td>Registration Lobby</td>
<td>Level -1</td>
</tr>
<tr>
<td>08.30 – 12.30</td>
<td>Symposium Scientific Sessions 9A/10A</td>
<td>Gold Hall</td>
<td>Level 0</td>
</tr>
<tr>
<td>08.30 – 12.40</td>
<td>Symposium Clinical Sessions 9B/10B</td>
<td>Copper Hall</td>
<td>Level 0</td>
</tr>
<tr>
<td>10.00</td>
<td>Refreshment break</td>
<td>Magritte Foyer</td>
<td>Level 0</td>
</tr>
<tr>
<td>12.30 – 14.00</td>
<td>Lunch</td>
<td>Grand Hall 2</td>
<td>Level -2</td>
</tr>
<tr>
<td>14.00 – 15.00</td>
<td>Symposium Joint Closing Session</td>
<td>Gold Hall</td>
<td>Level 0</td>
</tr>
</tbody>
</table>
With grateful thanks to the Platinum Sponsor of the 25th International Symposium on ALS/MND

Cytokinetics

and to the following symposium supporters

ALSTDI

CCA Clinical Research
TRIALS WITHOUT THE TRIBULATIONS
Provisional abstract submission deadline: 29 May 2015

For further information please contact
Motor Neurone Disease Association
PO Box 246 Northampton NN1 2PR
Tel: +44 (0) 1604 611 845
Fax: +44 (0) 1604 624 726
Email: symposium@mndassociation.org
Email: abstracts@mndassociation.org
www.mndassociation.org/symposium

Reg. Charity No. 294354